Podcasts about biotech

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

  Aging in Place: Safety, Technology, & Dignity w/ Drew Siefried of TruBlue Ally - AZ TRT S07 EP04 (286) 3-1-2026       Things We Learned This Week ·         America is aging rapidly - By 2030, 1 in 5 Americans will be over 65. ·         Most seniors want to stay in their homes - More than 80% of older adults prefer aging in place rather than moving to assisted living. ·         Technology is transforming senior safety - Non-intrusive monitoring systems can detect falls and alert families without cameras or wearables. ·         One fall can change everything - Falls are one of the leading causes of injury and loss of independence among seniors. ·         Prevention is far cheaper than crisis care - Simple home safety upgrades can prevent accidents and help seniors maintain independence longer.     Guest: Drew Seifried LKIN: https://www.linkedin.com/in/drewseifried/ Company: TruBlue Home Service Ally Website: https://www.trublueally.com/east-phoenix-north-scottsdale   With over 25 years of combined corporate and entrepreneurial experience, I currently own and operate TruBlue Home Service Ally, where we support seniors and busy families with home modifications and handyman services. In this role, we prioritize safety, reliability, and exceptional service, ensuring all personnel meet high professional standards. As a Certified Franchise Executive, I also guide aspiring entrepreneurs, including corporate professionals, first responders, and military veterans, toward business ownership through franchising. Leveraging expertise in franchise agreements and processes, I simplify the path to ownership, aligning opportunities with individual goals. My mission is to empower others to achieve their aspirations through purpose-driven ventures.   TruBlue Home Service Ally® provides a unique and affordable approach to helping busy adults and seniors live a worry-free life by offering trustworthy handyman, home maintenance and senior modification services. Helping you maintain your home both inside and out, TruBlue's services include: handyman projects and to-do list chores, preventative home maintenance programs, seasonal work, and senior modification services, all handled by a professional, bonded and insured Tru-Pro® Technician. Episode Overview America is entering a major demographic shift. By 2030, 1 in 5 Americans will be over the age of 65, creating what many experts call the "Silver Tsunami." Families across the country will face new challenges as aging parents want to maintain independence while staying safe at home. But aging at home safely requires planning. In this episode, we sit down with Drew Seifried of TruBlue Home Service Ally to discuss how home safety modifications, emerging Age Tech, and non-intrusive monitoring technologies are helping seniors stay independent longer — while providing peace of mind for their families. We also explore the unique needs of veterans and individuals with disabilities, and how communities and organizations can better support them.   Segment 1: Aging in Place & The Silver Tsunami Drew Seifried owns three territories with TruBlue, a national franchise focused on helping people safely remain in their homes. The company works primarily with: ·         Seniors and aging adults ·         People with disabilities ·         Veterans ·         Adult children caring for aging parents Their mission is simple: help people live independently and safely at home. The Growing Senior Population America is rapidly aging. Key statistics: ·         61 million Americans are age 65+ ·         By 2030, about 20% of the population will be seniors ·         Phoenix and other Sun Belt cities are seeing rapid senior population growth as retirees relocate This demographic shift will place new pressure on: ·         Healthcare systems ·         Caregiver workforce ·         Family members caring for aging parents The Hidden Risk: Falls in the Home One of the biggest threats to senior independence is falling. Key statistics: ·         1 in 4 adults age 65+ falls each year ·         Falls cause over 3 million emergency room visits annually ·         More than 300,000 seniors are hospitalized each year for hip fractures ·         Over 50% of falls occur inside the home In many cases, one fall can change everything. A serious fall can lead to: ·         Hospitalization ·         Loss of mobility ·         Long-term disability ·         Moving into assisted living The Most Dangerous Areas in a Home According to home safety experts, the highest risk areas include: ·         Bathrooms (tubs and showers) ·         Entryways and stairs ·         Poor lighting ·         Cluttered hallways or walkways Even small modifications can dramatically reduce fall risk. Preventing Falls Before They Happen TruBlue helps families install preventative safety upgrades such as: ·         Bathroom grab bars ·         Non-slip shower treatments ·         Improved lighting ·         Handrails and stair supports ·         Walkway hazard removal The company also performs full home safety assessments to identify hidden risks. As Drew explains, the goal is prevention — because once a fall happens, recovery can be much more difficult. Aging at Home vs Assisted Living Another major challenge families face is cost. Average assisted living costs in the U.S.: ·         $5,000–$6,000 per month ·         Often $60,000–$70,000 per year By comparison, many safety upgrades or in-home services cost a fraction of that. And most seniors prefer to stay home. Surveys show: ·         84% of seniors want to age in place ·         Independence and familiarity with their home environment matter deeply Segment 2: Age Tech & Smart Monitoring One challenge facing families is the shrinking caregiver workforce. With fewer caregivers available, technology is stepping in to help monitor safety. Adult children want peace of mind that their parents are safe — especially when they live in another city. But many seniors dislike traditional monitoring systems. Common concerns include: ·         Cameras in the home ·         Wearable emergency devices ·         Privacy issues ·         Technology complexity A New Approach: Radar-Based Monitoring A newer technology solution is radar-based monitoring systems like those from Pontosense. These systems use small radar sensors placed throughout the home. They can detect: ·         Falls ·         Movement patterns ·         Breathing and vital signals Unlike cameras, they are completely non-intrusive. Features include: ·         No cameras ·         No wearable devices ·         No audio recording ·         No stored video data The system can detect unusual events and send alerts. Smart Alerts for Families If a fall occurs, the system can: ·         Wait about 90 seconds to see if someone gets up (reducing false alerts) ·         Send notifications to family members ·         Contact caregivers ·         Alert emergency services if necessary Family members can also monitor activity patterns through a mobile app. For adult children balancing careers, families, and aging parents, this technology provides peace of mind without invading privacy. Segment 3: Disability Services & Veteran Support TruBlue also works with individuals living with disabilities and veterans who require specialized home modifications. Organizations supporting the disability community include: ·         Ability360 ·         Benevilla These groups offer programs ranging from adaptive sports to community support services. Health Challenges as We Age Many older adults face conditions that impact mobility or independence. These can include: ·         Arthritis ·         Balance issues ·         Progressive neurological diseases like ALS or MS ·         Reduced strength and coordination Simple tasks — getting into a bathtub, climbing stairs, or reaching shelves — can become difficult. Home modifications can restore independence. Importantly, these upgrades can be designed to blend into the home aesthetically, preserving both function and dignity. Supporting Veterans Veterans represent another group that often needs home safety support. Key statistics: ·         Approximately 17 million veterans live in the United States ·         Nearly 8 million veterans are age 65 or older Despite available programs, many veterans do not utilize assistance. Organizations working to support veterans include: ·         Paralyzed Veterans of America ·         Veterans of Foreign Wars ·         Elks Lodge Drew himself served in the military and is passionate about helping veterans access services and resources. Additional Home Safety Monitoring Beyond fall prevention, modern smart homes can also monitor: ·         Smoke and fire detection ·         Water leaks and flooding ·         Utility failures ·         Entry and exit activity These systems help families create a safer living environment for aging loved ones.   Final Takeaway Aging doesn't have to mean losing independence. With the right combination of: ·         Home safety modifications ·         Smart technology ·         Community resources ·         Family planning Millions of seniors can live longer, safer, and more confidently in their own homes.       'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

When scientists began tinkering with DNA in the 1970s, biotechnology was not welcome in leafy residential neighborhoods or many college towns. But it was embraced by an industrial city by the Bay. In today's episode we come to learn how South San Francisco became one of the world's most valuable hubs of biotech. Additional Resources: How South San Francisco Became the Birthplace of Biotechnology Read the transcript for this episode Sign up for our newsletter Got a question you want answered? Ask! Your support makes KQED podcasts possible. You can show your love by going to https://kqed.org/donate/podcasts This story was reported by Lesley McClurg. Bay Curious is made by Katrina Schwartz, Christopher Beale and Olivia Allen-Price. Additional support from Jen Chien, Katie Sprenger, Maha Sanad, Ethan Toven-Lindsey and everyone on Team KQED. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

John is joined by Jonathan Graham, Executive Vice President and General Counsel and Secretary of Amgen, one of the world's largest biotech companies and one of the pioneers of the industry. They discuss in-house legal leadership in major biotech companies and how science, intellectual property, and regulation shape strategy. Jonathan began his practice clerking for the Ninth Circuit Court of Appeals, then became a litigator for a large firm. Later, his career shifted in-house. He believes that litigation training develops useful skills, including rapid issue spotting across unfamiliar domains, crisp written and oral advocacy, and an ability to understand stakeholders' incentives.The biotech industry is unusually purpose-driven because the output is medicine that can extend life and restore quality of life. That mission creates urgency across functions, as delays can mean patients wait longer for needed therapies. The sector is also highly regulated and fast-moving, which elevates the importance of legal teams that operate as strategic partners rather than as a “department of no.”Intellectual property is the economic lifeblood of biological drug development. Bringing a molecule to market often costs billions of dollars and requires years of lab work, clinical trials, and manufacturing scale-up. Without enforceable patents, competitors could free ride, undermining investment incentives. This reality drives frequent, high-stakes patent disputes that can be hard to settle because exclusivity is enormously valuable.Patent doctrines often lag behind technology, forcing courts to fit new technologies into older legal frameworks. Artificial intelligence is potentially a powerful tool for discovery and analysis of molecules, but not a substitute for wet-lab validation or human inventorship. Regulators still require clinical evidence before any medicine is approved and likely will for the foreseeable future.Biosimilars are currently a booming market with many parallels to generic drugs. A company may participate in the market as both innovator and biosimilar supplier by leveraging its research and manufacturing capabilities. Finally, government-driven drug pricing controls may slow innovation over time, even though scientific progress and therapeutic potential remain strong.Podcast Link: Law-disrupted.fmHost: John B. Quinn Producer: Alexis HydeMusic and Editing by: Alexander Rossi

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll discuss how best to tailor an investment approach of both nondilutive funding and family offices to overcome the drug development valley of death. Host⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpaceGuestsRam May-Ron, Managing Partner, FreeMind GroupRavi Kiron, Managing Director, Biopharma Strategy AdvisorsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

This is for the woman who's aiming for a promotion (or a bigger external role) and keeps thinking, If I could just get that title, everything would feel different.Today we are going beyond the title to talk about the messy middle, what drives advancement and the critical part needed to reach your advancement goal. When you don't understand your deeper “why,” you can end up pushing for something that isn't actually the solution… or finally getting it and realizing it feels hollow.In this episode, you'll learn:Why I ask “why” first when someone says they want a promotion title—and the common answers that quietly stall progressThe three deeper drivers I hear most often and what each one actually requires in Pharma/BiotechWhy “I earned it” and “I work hard” rarely works as a promotion strategy in complex organizationsGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Math doesn't have to be intimidating, especially when it's the kind that helps fund companies and move science forward. In this episode, host Elaine Hamm, PhD, is joined by Isaiah Reeves, PhD, Biomedical Analyst at Solas BioVentures, for a practical and approachable deep dive into venture math. Drawing on his background as a scientist turned investor, Isaiah breaks down the core financial concepts every biotech founder should understand: from valuations and dilution to IRR, cap tables, and deal terms. The conversation offers real-world guidance for navigating fundraising, choosing the right partners, and avoiding common pitfalls that can derail long-term value creation. In this episode, you'll learn: How venture capitalists think about valuations, dilution, and returns, and why fully diluted post-money matters. Key metrics like IRR and DPI, and how they influence investment decisions and fund performance. Common deal terms and cap table “red flags” founders should watch out for as they raise capital. Tune in to learn how understanding venture math can help founders make smarter funding decisions, protect long-term value, and build biotech companies positioned for sustainable growth and impact. Links: Connect with Isaiah Reeves, PhD, and check out Solas BioVentures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine, as well as Cadenza Bio. Connect with Josh Eckelberry, MBA, and Mark Corrigan, MD. Check out the books The Go-Giver and Venture Deals. Check out the podcasts STAT, Biotech Hangout, and 20VC. Check out our previous episodes on Networking as an Introvert and Solas BioVentures with Travis Manasco. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

From academic deep‑tech to the front lines of Biotech entrepreneurship - Eline Koers' journey is a masterclass in courage, clarity, and reinvention. After years immersed in structural biology and membrane protein folding, Eline realised she wanted her work to have real‑world impact. That shift pulled her out of academia, into translational science, and eventually into founding AAB Therapeutics - a company engineering extracellular vesicles to solve one of oncology's biggest challenges: getting drugs where they need to go. In this conversation, Eline shares the turning points that shaped her path, discussing the importance of curiosity, timing, and daring to step into the unknown - even when the success rate is small and the learning curve is steep. A brilliant episode for anyone considering a move from academia into Biotech, or thinking about building something of their own.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Patients who need kidney dialysis live all over the world - even in some of the remotest regions. They need updated equipment, trained healthcare staff, and lots of clean water. Chris Atwater, Director of Technical Operations at the nonprofit Bridge of Life, helps bring hope to these areas. He has traveled to six continents for his life's work, using skills he learned as a United States Marine and the education he acquired for this role. If you are interested in learning more about challenges facing dialysis patients in remote areas, check out this video we made about services in the Australian bush. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

Doug Crawford, Ph.D., is the founder of MBC BioLabs and also a Managing General Partner of Mission BioCapital. Doug's goal is to help entrepreneurial scientists create successful startups. His dream is that every entrepreneurial scientist with a dream be given a chance.  Since its founding, this program has helped launch 500 companies and helped raise over $20 billion in capital. Robert Blazej, Ph.D., is a Partner at Mission BioCapital and Director at MBC BioLabs. He is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that microdroplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. This conversation can be considered as the 2026 State of the Union for early-stage biotech. The biotech landscape has shifted drastically- we moved from the grow-at-all-costs zero-interest-rate era to a world of tight capital and high discipline. The undisputed capital of biotech in Boston is facing unprecedented lab vacancies. AI is dominating every pitch deck. And China has rapidly evolved from a manufacturing hub into a multi-billion-dollar discovery engine.   Shownotes https://mbcbiolabs.com/; https://www.missionbaycapital.com/ How did Doug and Robert meet? Progress Mission Biolabs made in the past 4 years God's eye view of the biotech startup world- What is being built? DNA of the founders: repeat founders on the rise Capital restraints and advances in science made the current period the best time to launch biotech startups. With the advent of AI, we should not be making knowable mistakes Companies are using AI to jumpstart what they are going to work on Discovery costs are the overall cost of drug discovery- So, don't get too excited! How to address reduction in NIH non-dilutive funding ⅓ of startups in incubators are serial entrepreneurs; ⅓ are mid-career scientists from established companies  Comparing Boston and the Bay area biotech ecosystems 73% of pharma's revenues are from discoveries sourced externally Alternate models: Arena bioworks, Arc Institute, Chan Zuckerberg institute Book recommendation - Thinking in Bets Actual impact of AI at Mission Biolabs Where Ai might have the most impact- healthcare delivery? China affairs: Regulatory changes, investments, return of talent European biotech affairs

Navigating Talent Optimization: Strategic Staffing and Leadership with Robert HowardIn this episode of The Thoughtful Entrepreneur Podcast, host Josh Elledge speaks with Robert Howard, Director of Recruiting Operations and Executive Leadership Coach at Magic Talent Solutions, about the evolving complexities of the modern workforce. As a military veteran and seasoned business owner, Robert brings a unique perspective to the high-stakes world of recruitment, offering deep dives into bridging staffing gaps and upskilling internal teams. This conversation serves as a strategic guide for founders and executives who are navigating the post-pandemic market correction and seeking to balance the efficiency of AI with the irreplaceable value of human judgment in leadership.Optimizing the Human Element in Modern RecruitmentThe current recruiting landscape requires a sophisticated blend of agility and specialized expertise to overcome the "ebb and flow" of market demands. Robert observes that while many organizations surged with over-hiring in previous years, 2026 is defined by stabilization and a more project-based approach to talent acquisition. For companies struggling with mission-critical, hard-to-fill roles, the solution often lies in moving beyond basic job postings toward advanced sourcing strategies that identify passive talent. By aligning staffing levels with specific project needs and maintaining a flexible workforce of both full-time and contract professionals, businesses can protect their bottom line while ensuring they have the right hands on deck for every initiative.Transitioning from an individual contributor to a leadership role remains one of the most common stumbling blocks for growing enterprises. Robert emphasizes that effective leadership development is not a "one-size-fits-all" endeavor; it requires tailored coaching that draws on proven principles of communication and accountability. Many companies find their internal recruiting teams are comprised of junior staff who lack the nuance required for high-level interviewing or the deep understanding of complex employment laws, such as those specific to California. Upskilling these internal teams through hands-on training ensures that the first point of contact for new talent is professional, compliant, and capable of identifying the subtle cultural fits that drive long-term retention.The integration of AI in recruitment offers significant efficiency gains, but it also introduces new risks regarding bias and candidate experience. While AI excels at administrative heavy lifting—such as interview scheduling and bulk follow-ups—Robert cautions that it is not yet a reliable substitute for human intuition in the final selection process. Relying solely on algorithms for candidate screening can lead to unintentional bias and even legal complications. Successful organizations use AI as a tool to free up their human recruiters for high-value relationship building, ensuring that the final "yes" is always determined by a person who can sense the intangible qualities that make a candidate truly exceptional for a specific team.About Robert HowardRobert Howard is the Director of Recruiting Operations at Magic Talent Solutions and a dedicated Executive Leadership Coach. With a background rooted in military service and entrepreneurial leadership, he specializes in identifying talent patterns and helping organizations build high-performing teams. Robert is passionate about professional development, often using his experience as an escape room enthusiast to teach the principles of collaborative problem-solving and strengths-based task management.About Magic Talent SolutionsMagic Talent Solutions is a premier staffing and consultancy firm founded to help businesses navigate the shifting talent landscape. The company provides a holistic approach to people operations, offering specialized recruiting for Biotech, Marketing, and Commercial Sales, alongside internal team training and executive leadership coaching. Magic Talent Solutions focuses on bridging the gap between current organizational capabilities and the high-level talent required to achieve strategic goals.Links Mentioned in This EpisodeMagic Talent Solutions Official WebsiteRobert Howard on LinkedInKey Episode HighlightsThe Metaphor of the Escape Room: Why pattern recognition and playing to individual strengths are the secrets to solving both literal puzzles and business bottlenecks.Recruitment Upskilling: The necessity of training internal hiring teams to handle complex employment regulations and sophisticated candidate sourcing.The 2026 Market Correction: Navigating the shift from over-hiring to stabilized, project-based staffing strategies.AI vs. Human Judgment: Why administrative automation is a win, but candidate selection still requires a human touch to avoid bias.Leadership Transitions: Strategies for helping top-tier individual contributors successfully move into management and executive roles.The conversation with Robert Howard illuminates the path for businesses that want to move away from reactive hiring and toward proactive talent optimization. By investing in the training of internal teams and maintaining a human-centric approach to leadership, organizations can build a resilient culture that attracts and retains the best in their industry.More from The Thoughtful Entrepreneur

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a "GI tract on a chip"), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex's platform technology before scaling it out. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a professor at the Oklahoma Medical Research Foundation, explains why physiology remains central to biomedical innovation. Bodine details how physiology strengthens biotech and pharmaceutical research by clarifying how therapies behave in complex biological systems, identifying unintended effects and supporting stronger regulatory narratives. She also examines the expanding role of physiology in wearable technology, remote patient monitoring and artificial intelligence, where biological context is essential to turning large data sets into clinically meaningful insights. The episode also highlights the society’s campaign, “Physiology: The Science Life Depends On,” aimed at elevating awareness of foundational science amid funding uncertainty. For executives, investors and health care leaders seeking sustainable innovation and patient impact, this discussion underscores a clear message: Breakthroughs depend on physiology. Listen to the full interview.See omnystudio.com/listener for privacy information.

In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

This Biotech CEO Is Helping Prevent Surgical Infections – Meet Dikla Czaczkes Akselbrad, CEO PolyPid $PYPDGuestDikla Czaczkes Akselbrad, CEO PolyPidCompany PolyPidhttps://www.polypid.com/Ticker: $PYPDDikla's BioMs. Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid after serving as the company's EVP and CFO since 2017, leading the company's initial public offering on the Nasdaq Global Market in June 2020. Dikla brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles. Before joining PolyPid in 2014, Dikla served as CFO of Compugen Ltd. (NASDAQ & TASE: CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world's first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Guest: Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBioCompany: iBio, Inc. (NASDAQ:IBIO)Website: https://ibioinc.com/Martin's Bio:Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Company Description: iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Politics can feel overwhelming - but how can scientists, founders, and biotech leaders effectively engage with policymakers to protect innovation and improve patient outcomes? In this episode, host Elaine Hamm, PhD, is joined by Srinu Sonti, JD, Principal at Lewis-Burke Associates LLC, for a candid and insightful conversation on science, policy, and advocacy. Drawing on his experience on Capitol Hill, in health policy, and working with academic medical centers and startups, Srinu breaks down how innovation, funding, and regulation intersect - and why it's critical for scientists and biotech leaders to have a voice in the policy process. In this episode, you'll learn: Why policymakers want to hear directly from scientists, founders, and innovators, and how those conversations shape decisions. Practical ways universities, startups, and small teams can engage lawmakers beyond sending emails or reacting to crises. How policy choices around clinical trials, AI, global collaboration, and advanced therapies impact patients and the future of biotech. Tune in to learn how building authentic relationships with policymakers can demystify science, strengthen innovation ecosystems, and help move life-saving technologies from the lab to the people who need them most. Links: Connect with Srinu Sonti, JD, and check out Lewis-Burke Associates LLC. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Pew Charitable Trusts. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My book, Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech is officially out today, and in this special bonus episode, my marketing assistant turns the tables and interviews me about why I wrote this book, how the method came to be, and what I want the reader to feel by the end of it.This isn't a traditional teaching episode. It's more a behind-the-scenes conversation. We talk about the roadblocks I hit in my own 9-to-5, the moment I was told my extra degree and stretch work didn't “count,” and how that experience led me to develop the hidden doors framework.This is honest, unscripted, and be sure to listen to the end to catch the blooper reel.In this episode, you'll learn:The reason I wrote this book — and why I wanted it accessible to every woman in scienceThe story behind “hidden doors” and how roles get created outside the org chartThe career advice I followed early on that slowed me downWhat surprised me most while writing — including what I chose to leave outWhat I hope you feel when you finish the last chapterGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Plus: Renault to take full control of Flexis electric-van. And Nvidia chips for laptop computers set to hit the market this year. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of the Crazy Wisdom Podcast, host Stewart Alsop sits down with Jake Hamilton, founder of Groundwire and Nockbox, to explore zero-knowledge proofs, Bitcoin identity systems, and the intersection of privacy-preserving cryptography with AI and blockchain technology. They discuss how ZK proofs could offer an alternative to invasive identity verification systems being rolled out by governments worldwide, the potential for continual learning AI models to shift the balance between centralized and open-source development, and why building secure, auditable computing infrastructure on platforms like Urbit matters more than ever as we face an explosion of AI agents and automated systems. Jake also explains Nockchain's approach to creating a global repository of cryptographically verified facts that can power trustless programmable systems, and how these technologies might converge to solve problems around supply chain security, personal data sovereignty, and resistance to censorship.Timestamps00:00 Introduction to Groundwire and Knockbox02:48 Understanding Zero-Knowledge Proofs06:04 Government Adoption of ZK Proofs08:55 The Future of Identity Verification11:52 AI and ZK Proofs: A New Era14:54 The Role of Urbit in Technology18:03 The Impact of COVID on Trust20:51 The Evolution of AI and Data Privacy23:47 The Future of AI Models26:54 The Need for Local AI Solutions29:51 Interoperability of Knockchain and BitcoinKey Insights1. Zero-Knowledge Proofs Enable Privacy-Preserving Verification: Jake explains that ZK proofs allow you to prove computational outcomes without revealing the underlying data. For example, you could prove you're over 18 without exposing your full identity or driver's license information. The proof demonstrates that a specific program ran through certain steps and reached a particular conclusion, and validating this proof is fast and compact. This technology has profound implications for age verification, identity systems, and protecting privacy while maintaining necessary compliance, potentially offering a middle path between surveillance states and complete anonymity.2. Government Adoption of Privacy Technology Remains Uncertain: There are three competing motivations driving government identity verification systems: genuine surveillance desires, bureaucratic efficiency seeking, and legitimate child protection concerns. Jake believes these groups can be separated, with some officials potentially supporting ZK-based solutions if positioned correctly. He notes the EU is exploring ZK identity verification, and UK officials have shown interest. The key is framing privacy-preserving technology as protection against "the swamp" rather than just abstract privacy benefits, which could resonate with certain political constituencies.3. The COVID Era Destroyed Institutional Trust at Unprecedented Scale: The conversation identifies COVID as potentially the largest institutional trust-burning event in human history, with numerous institutions simultaneously losing credibility with large portions of the population. This represents a dramatic shift from the boomer generation's default trust in authority figures and mainstream media. This collapse is compounded by the incoming AI revolution, creating a perfect storm where established bureaucracies cannot adapt quickly enough to manage rapidly evolving technology, leaving society in fundamentally unmanageable territory.4. Centralized AI Models Create Dangerous Dependencies: Both speakers acknowledge growing dependence on centralized AI services like Claude, with some users spending thousands monthly on tokens. This dependency creates vulnerability to price increases and service disruptions. Jake advocates for local AI deployment using models like DeepSeek R1, running on personal hardware to maintain control and privacy. The shift toward continuous learning models will fundamentally change the AI landscape, making personal data harvesting even more valuable and raising urgent questions about compensation and consent for training data contribution.5. High-Quality Training Data Is Becoming the Primary AI Bottleneck: Stewart argues that AI development is now limited more by high-quality training data than by compute power. The industry has exhausted easily accessible internet data and body-shop-style data labeling. Companies are now using specialized boutique services with techniques like head-mounted cameras for live-streaming world model training. This scarcity is subtly driving price increases across AI services and will fundamentally reshape the economics of AI development, with implications for who controls these increasingly powerful systems.6. Urbit Offers a Foundation for Trustworthy Computing: Jake positions Urbit as essential infrastructure for the AI age because its 30,000-line codebase (versus Unix's three million lines) can be understood by individual humans. Its deterministic, purely functional, and strictly typed design aims for eventual ossification—software that doesn't require constant security patches. This "tiny and diamond perfect" approach addresses the fundamental insecurity of systems requiring monthly vulnerability patches. In an era of AI agents and potential prompt injection attacks, having verifiable, comprehensible computing infrastructure becomes existentially important rather than merely desirable.7. Nockchain Creates a Global Repository of Provable Truth: Jake's vision for Nockchain combines ZK proofs with blockchain technology to create a globally available "truth repository" where verified facts can be programmatically accessed together. This enables smart contracts or programs gated on combinations of proven facts—such as temperature readings from secure devices, supply chain events, and payment confirmations. By using Nock's abstract, simple design optimized for ZK proof generation, the system can validate complex real-world conditions without exposing underlying data, creating infrastructure for coordinating action based on verifiable private information at global scale.

A new federal law is about to require contractors to map their supply chains, vet their vendors, and prove they're not relying on banned biotech companies. Many firms will discover exposure they didn't know they had. We'll explain what's at stake with Alex Major, Partner and Co‑Chair of the Government Contracts & Global Trade Practice at McCarter & English.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

February 13, 2026: AI in Drug DiscoveryIt costs $2.5 billion and up to 10 years of effort to successfully bring a new drug to market.That's an extremely high hurdle to succeed!It's no wonder why the high costs of FDA trials & the elevated rates of failure often result in small-cap drug developers declaring bankruptcy. Biotechnology is one of the stock market's riskiest sectors to invest in.But what if there was a way to change that?What if we could use technology to alleviate some of the biotech industry's deepest and most systemic risks?AI doesn't necessarily produce better drugs. Though it might be able to reduce drug development costs and timelines significantly.And if it did, that would be a game-changer for the entire industry.On today's show, my special guest Manisha Samy and I will discuss how AI-native infrastructure could vastly improve the return profiles of early-stage biotech companies.Our stock of focus will be Recursion Pharmaceuticals (Nasdaq: RXRX) who's creatively using AI to guide several programs in its development pipeline.

This episode is brought to you by B2B Better. We turned down SaaS clients and e-commerce brands to become the only video-first podcast agency for service-based B2B businesses. Specificity is the strategy.  If you've ever said "we can do that" to every client who walks in, this episode is your wake-up call. Host Jason Bradwell breaks down why niching down is the fastest path to becoming the obvious choice, and why being a bit of everything for everyone means you're actually nothing for nobody. Jason's core point is clear: when he set out to build B2B Better, he committed to being specific on two levels - who they serve and what they do. Not just B2B, because B2B is a hemisphere. They went one layer deeper: service-based businesses. Consulting firms, agencies, system integrators, compliance specialists. Companies that sell expertise, not products. People, not software. Trust and relationships, not features and pricing. That's what lends itself to their service: video-first podcasts that turn your point of view into pipeline. Nothing else. The same principle applies to podcasts. When a client says they want to launch a show, Jason's first question is: what's your superpower? Here's the formula. "This is a podcast about X, and unlike other podcasts about X, only we do Y." Most B2B podcasts fail this test. They say "we're a podcast about technology" or "leadership" or "AI." So are thousands of others. There's no "and." There's no reason to choose you. Add the "and" and everything changes. One show in the B2B Better portfolio is Data and Biotech: "a podcast about data science, and unlike other data science podcasts, only we explore it through the lens of biotech manufacturing." Suddenly if you're a data scientist in biotech, there's only one show for you. That specificity drives 75% to 80% episode completion rates, nearly double the industry average because every listener is exactly the right person. The fear of niching down is real. Every founder worries about leaving money on the table. But saying yes to everyone dilutes your positioning, creates operational inefficiency, and kills pricing power. What actually happens when you niche properly: the funnel gets narrower at first, but the people who raise their hand are perfect fits. They convert faster, pay more, stay longer, and refer others in the same niche. Year one it feels limiting. Year three it feels like leverage. Year five it feels like a moat. The framework to choose your niche: look at your best clients, not biggest. Validate the economics. Test your thesis before announcing publicly. Then commit hard and communicate clearly—change the website, the LinkedIn, the pitch deck. Say who you serve and who you don't. Resonance over reach. Always. Chapter Markers 00:00 - The "we can do anything" agency problem 01:00 - Why B2B isn't a niche, it's a hemisphere 02:00 - Choosing service-based businesses as the core niche 03:00 - Selling expertise, not products: why podcasts fit perfectly 04:00 - Video-first podcasts and the full service offering 05:00 - The superpower formula for podcast positioning 06:00 - Data and Biotech: the power of the "and" 07:00 - 75 to 80% completion rates and what resonance looks like 08:00 - Deeply engaged beats loosely interested every time 09:00 - Addressing the fear of leaving money on the table 10:00 - How niching compounds: pricing, referrals, close rates 11:00 - Four-step framework to choose your niche 12:00 - Specialists compound, generalists reset to zero 13:00 - Resonance is a revenue metric, reach is vanity 14:00 - Direct, systematic, results-driven: the B2B Better approach 15:00 - Write your "and" statement this week Useful Links Connect with Jason Bradwell on LinkedIn Listen to Pipe Dream on Podbean Explore B2B Better website and the Pipe Dream podcast 

John Cumbers returns to the Grow Everything podcast for his fourth appearance to discuss the cutting edge of synthetic biology and the upcoming SynBioBeta 2026 conference. From a man who's been bitten by snakes over 200 times to create universal anti-venom, to the race between the US and China in bio-manufacturing, John reveals why the bioeconomy is reaching an inflection point. We explore how AI is transforming organism design, the $50 million deals being struck for AI models in pharma, and why Chinese bio-manufacturing firms are achieving profitability while Western companies struggle. John also shares his vision for cellular reprogramming and longevity, discusses the controversial rollback of US environmental policy, and explains why the "ChatGPT moment" for biology is closer than we think. Plus, learn about stem cell tissue banks that could revolutionize replacement therapy and why SynBioBeta 2030 will actually happen on the moon.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Welcome Back: John Cumbers' Fourth Appearance on Grow Everything(00:01:00) - Death Becomes Her: Longevity on Broadway(00:03:00) - Listening Bars and Ambient Music Experience(00:04:00) - The Peptide Revolution: From Gray Market to Mainstream(00:07:00) - Trump Administration Revokes Clean Air Act: Impact on Biotech(00:12:00) - Biomanufacturing as Economic Development and Climate Solution(00:13:00) - AI, Space, and Solar Energy: Elon Musk at World Economic Forum(00:16:00) - Data Centers in Space: The Future of Energy(00:18:00) - Introducing John Cumbers and SynBioBeta 2026(00:19:00) - The Man Bitten by 200+ Snakes: Universal Anti-Venom Story(00:22:00) - The Schmidt Pain Index and Extreme Science(00:23:00) - History and Evolution of SynBioBeta Over 14 Years(00:25:00) - Bio 500: Big Companies Transforming with Biotech(00:27:00) - Plant-Based Sales Slowdown and Consumer Bio Trends(00:30:00) - Discovery vs. Commercialization: Why 80% of Startups Fail on Execution(00:34:00) - Default Alive Companies: Bootstrapping the Bioeconomy00:36:00) - AI Meets Biology: When's the ChatGPT Moment?(00:39:00) - Sidewinder DNA Assembly: Revolutionary Build Technology(00:42:00) - Design-Build-Test-Learn: Closing the Loop with Self-Driving Labs(00:43:00) - China's Biomanufacturing Dominance: What the West Can Learn(00:49:00) - Free Market Capitalism vs. Centralized Planning(00:52:00) - Should SynBioBeta Take Political Stands?(00:55:00) - Longevity Revolution: Cellular Programming and Stem Cell Banks(00:59:00) - Death Becomes Her and the Market for Living Forever(01:01:00) - AI and Bio: The Singularity is Here(01:03:00) - Human Genome Engineering and the Meta Simulation(01:05:00) - Quick Fire Round: Lantern Bioworks, Moon Conference, and Awards(01:07:00) - Closing: SynBioBeta Discount Code and Final ThoughtsLinks and Resources:Synbiobeta website. Join us! Use code: "Grow Everything" for a discountOneSkinReplacement theory of aging - Jean HebertTopics Covered:synbio, synthetic biology, bioengineering, conferences, networks, biotech, biology, bioliteracy, Bio500, AI and BioHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠Instagram⁠⁠ / ⁠⁠Twitter⁠⁠ / ⁠⁠LinkedIn⁠⁠ / ⁠⁠Youtube⁠⁠ / ⁠⁠Grow Everything⁠⁠Music by: Nihilore Production by: Amplafy Media

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from scientific breakthroughs to regulatory shifts and strategic corporate maneuvers.Let's start with Insmed's Brinsupri, a newly approved respiratory therapy that has captured attention with its projected $1 billion in sales by 2026. This ambitious forecast is grounded in Brinsupri's robust clinical efficacy and the increasing demand for innovative respiratory treatments. This development reflects a broader industry trend where targeted therapies are not only improving patient outcomes but also driving significant revenue growth. As respiratory conditions continue to be a major health challenge globally, the success of therapies like Brinsupri underscores the potential for innovation to meet these critical needs.In parallel, Merck is working strategically with its RSV antibody, Enflonsia, seeking a second-season approval to bolster its competitive stance against Sanofi and AstraZeneca's Beyfortus. The race in infant RSV prevention is intense as companies vie to establish dominance in this crucial segment of infectious disease management. Merck's efforts highlight the broader push within the industry to develop preventive measures that could significantly alter public health landscapes by reducing the incidence of severe respiratory illnesses in vulnerable populations.Meanwhile, regulatory scrutiny remains a constant for pharmaceutical companies. The FDA's recent review of Johnson & Johnson's advertising for Tremfya, targeting ulcerative colitis, emphasizes the agency's commitment to ensuring that efficacy claims are both truthful and transparent. This serves as a reminder of the importance of maintaining regulatory compliance and ethical advertising practices within the industry—a critical aspect as companies navigate complex marketing landscapes while ensuring patient trust.Shifts in leadership within key health organizations are also noteworthy. Jay Bhattacharya stepping into the role of acting CDC chief after Jim O'Neill's departure could signal changes in public health policy and research priorities. Such transitions can have profound effects on how emerging health challenges are addressed, potentially influencing everything from vaccine distribution strategies to research funding allocations.As we turn to policy discussions, President Donald Trump's most favored nation drug pricing proposal continues to stir debate. This initiative aims to lower drug prices by benchmarking them against international rates, but it faces resistance from free-market advocates who argue it could stifle pharmaceutical innovation. The ongoing discussion around drug pricing reform is pivotal, as it impacts both patient access to medications and the incentives for companies to invest in new drug development.Strategic realignments in the contract development and manufacturing organization (CDMO) sector are also making headlines. Recipharm's sale of its Israeli API plant to Scinai Immunotherapeutics, alongside a new CDMO partnership, illustrates how companies are optimizing resources to focus on core competencies and expand service offerings. This strategic shift highlights the dynamic nature of CDMOs as they adapt to changing market demands and technological advancements.In Alzheimer's research, there's promising news with a study suggesting that a blood test could predict when symptoms will appear, representing a significant leap forward in early diagnosis and intervention strategies. These advancements offer hope for altering the treatment landscape of neurodegenerative diseases through timely therapeutic interventions that could improve quality of life for patients. However, challenges remain as seen with Johnson & Johnson pausing enrollment in itsSupport the show

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Gregory: I have the ability to recognize and reframe patterns.Startup failure rates have hovered around 90% for over 30 years. Gregory Shepard, Founder and CEO of Startup Science, decided to tackle this persistent challenge with a comprehensive, science-backed approach. His goal is nothing short of transformative: to reduce failure rates and create a better ecosystem for entrepreneurs.Gregory's research revealed that 47.1% of startups fail within the first 18 months, with the remaining failures often linked to poor decisions made during that critical period. “There's no industry I can think of that would be okay with 90% of the people trying to succeed failing,” he explained. “I decided to do something about it.”Startup Science offers a centralized platform where entrepreneurs, investors, mentors, and support organizations can connect and collaborate. Gregory has worked to eliminate fragmentation in the startup ecosystem by providing tools, resources, and education—all free for founders. This mission is fueled by his belief that entrepreneurship drives innovation and can create opportunities for people from all backgrounds.Gregory's commitment to democratizing entrepreneurship extends to the way he's raising funds for Startup Science. He's launched a regulated crowdfunding campaign on Wefunder, allowing anyone—not just accredited investors—to support his mission. “If somebody invests in Startup Science, you're investing into all of the startups that we're helping, which is 100,000 of them at the moment,” he said.Gregory's passion is deeply personal. Growing up in poverty, he understands the barriers many entrepreneurs face. That empathy drives his vision to create an accessible, equitable platform that empowers founders to succeed while transforming the global economy.By leveraging his scientific approach to analyzing startup success and failure, Gregory is helping entrepreneurs avoid predictable pitfalls and build sustainable businesses. His efforts could fundamentally reshape the entrepreneurial landscape, enabling innovation to thrive.To learn more or support this initiative, visit Startup Science's crowdfunding campaign. This is an opportunity to back a proven entrepreneur who's committed to doing good for the world.tl;dr:Gregory Shepard shares his mission to reduce startup failure rates with his platform, Startup Science.Startup Science connects fragmented startup ecosystem elements, offering free tools and resources for founders.Gregory discusses his scientific research on startup success and his passion for democratizing entrepreneurship.He highlights his Wefunder campaign, inviting anyone to invest in Startup Science and support entrepreneurs.Gregory explains his superpower, pattern recognition, and how it drives his success in building ecosystems.How to Develop Pattern Recognition As a SuperpowerGregory's autistic diagnosis has sharpened his ability to identify and reframe patterns; a skill he calls pattern recognition. “I have the ability to recognize and reframe patterns…startup science is a result of this,” he explained. Gregory sees connections others might overlook, enabling him to create solutions that integrate fragmented systems into cohesive ecosystems. He describes it as understanding how seemingly separate components interact, much like a solar system where the founder is the sun and other elements orbit around them.Gregory's superpower was pivotal in building and selling Affiliate Traction to eBay Enterprise Marketing Solutions. He noticed that affiliate marketing—now a cornerstone of influencer marketing—was fragmented, with disconnected tools and processes. Gregory envisioned a unified system and developed software that brought these elements together. By connecting the dots, he transformed the industry and created a successful company, later replicating this approach with other ventures.Tips for Developing Pattern Recognition:Identify the structure of a system or process by analyzing its components and relationships.Observe how elements interact within a system and look for inefficiencies or gaps.Reimagine connected systems as an ecosystem where all parts work collaboratively.Practice applying this framework in various contexts, from business to social environments.By following Gregory's example and advice, you can make pattern recognition a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Register Now!Guest ProfileGregory Shepard (he/him):Founder and CEO, Startup ScienceAbout Startup Science: Startup Science is the unified platform for the startup ecosystem, built to support founders and the organizations that help them succeed.We serve entrepreneurs, accelerators, universities, government programs, mentors, investors, and service providers in one connected system, so everyone operates with shared structure, shared data, and clearer outcomes.Entrepreneur Support Organizations work with Startup Science to provide modern program management infrastructure to run their cohorts, deliver consistent curriculum, track founder progress, and report measurable impact, without reinventing the process every cycle.Founders gain access to trusted education, tools, and ecosystem support in one place as they work with their advisors, software and service providers, and other key stakeholders to build their companies.Our mission is to bring clarity, coordination, and effectiveness to entrepreneurship at scale. Website: startupscience.ioCompany Facebook Page: facebook.com/bossstartupscienceInstagram Handle: @startupscience.io Other URL: wefunder.com/startupscienceBiographical Information: Gregory Shepard is a visionary entrepreneur and business leader who has built and sold twelve companies across BioTech, TransitTech, AdTech, and MarTech. In 2016, he sold two of his businesses in a landmark $925 million cross-brand deal, earning four private equity awards.In 2024, he published The Startup Lifecycle with Penguin Random House, receiving acclaim from global leaders and institutions. He has contributed over 100 articles to major publications, hosted Startup Science on Forbes Radio, and co-founded the Fulbright Entrepreneurship Initiative.A sought-after speaker, Shepard has delivered keynotes at TEDx, Ivy League universities, and top conferences worldwide. His personal journey—from overcoming dyslexia, neurodivergence, and poverty to becoming a serial entrepreneur—adds depth to his inspiring message.Committed to “altruistic capitalism,” he integrates social and environmental responsibility into business. His journey proves that with passion, resilience, and a willingness to challenge convention, extraordinary success is within reach.LinkedIn Profile: linkedin.com/in/gregshepardInstagram Handle: @gregshepard_ Personal Twitter Handle: @GregShepard_The Super Crowd, Inc., a public benefit corporation, is proud to have been named a finalist in the media category of the impact-focused, global Bold Awards.Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include rHealth, and SuperCrowd26 featuring PurposeBuilt100™️. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on March 17th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

This job market needs a different approach - tune in to hear why. If you've been applying to roles, asking for promotions, taking on stretch work, and getting ghosted or hearing “not yet” or “there's no budget,” this conversation is for you.When budgets tighten and leaders become selective, performance alone isn't enough. In these environments, they don't promote or hire “good enough.” They move toward the person who feels necessary. And when the rules aren't clear, it's easy to internalize stalled growth as a personal failure instead of a strategic gap.So I'm also going to share the insider conversations that happen behind closed doors of leadership meetings.In this episode, you'll learn:Why performance reviews and stretch assignments don't automatically lead to advancementWhat talent conversations actually focus on behind closed doorsHow lack of clarity gets exposed quickly in a tight marketWhy perception and positioning matter as much as credentialsDetails about my book releasing February 24th - Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech.If you've been wondering why it feels harder than it should, this episode will help you see what's really happening—and what to think about differently.Book Waitlist: My book is available February 24th! Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech join the waitlist here. Are you a woman in Pharma/Biotech who wants to improve her career? Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Where do scientific breakthroughs really begin, and how much space do we leave for curiosity, intuition, and creative thinking along the way? In this episode, host Elaine Hamm, PhD, is joined by Auni Williams, PhD, a postdoctoral scholar at Penn State University, for a thoughtful and refreshing conversation about “night science.” Together, they explore the idea that behind every polished grant, publication, or protocol is a messier, more human process driven by curiosity, imagination, and the freedom to explore unconventional ideas. From historical examples of scientific breakthroughs to personal stories from the lab, this episode invites listeners to rethink how discovery really happens. In this episode, you'll learn: What “night science” is and why embracing early, unpolished ideas is critical for innovation and discovery. How modern research culture can unintentionally suppress creativity – and what institutions and leaders can do to protect exploratory thinking. Why communicating science as a human, curiosity-driven process is essential for engaging both scientists and the public. Tune in to learn how making space for curiosity, creativity, and night science can reignite passion for research and lead to the next generation of scientific breakthroughs. Links: Connect with Auni Williams, PhD, and learn more about Penn State University. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about François Jacob, Barry Marshall, August Kekulé, Operation Everest, American Heart Association Funding, and Cormac McCarthy's essay. Listen to our previous episode with Walter Isaacson. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This Biotech Stock Is Disrupting Cancer Treatment - Meet Raphi Levy, CFO, Alpha Tau $DRTSGuest Raphi Levy, CFO, Alpha Tau Company Alpha TauTicker: $DRTSWebsite https://www.alphatau.com Raphi's BioRaphi Levy has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel.Mr. Levy has served as a director of MX Management LP since April 2022. Mr. Levy holds a B.S. in Economics from the Wharton School of Business, University of Pennsylvania, and a B.S.E. and M.S.E. in Electrical Engineering from the School of Engineering and Applied Science, University of Pennsylvania. Company BioAbout Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

When Terry Pirovolakis learned his son had an ultra-rare neurodegenerative disease, SPG50, he refused to accept “no options.” What started as a desperate search for hope became Elpida Therapeutics, a nonprofit driving gene therapy innovation for multiple rare diseases. In this episode, Terry shares the remarkable journey from diagnosis to clinical trials, the power of partnerships, and why urgency matters when every day counts.Show NotesFrom Mystery to Medicine: The Science Behind a Mother's Search | PodcastTaking a Customized and Collaborative Approach to Therapeutic Development | PodcastRare Disease Research for Drug Development | Charles RiverRare Disease | Charles RiverDiscovery | Charles RiverBeyond The Diagnosis

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhanFollow Jorge Conde on X: https://x.com/JorgeCondeBio  Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Live Feb 10, 2026 | Yaron Brook ShowSeason 12, Episode 26Bridge to?; TrumpRx; Climate Regs; Internet addiction; Discord; SpaceX; Russia | Yaron Brook ShowIs America Building a Bridge to Greatness… or to Decline? From TrumpRx to Climate Controls, SpaceX to Russia — Nothing Is Off Limits.Is America building a bridge to the future — or a bridge to nowhere?In this explosive episode of The Yaron Brook Show, Yaron takes on everything from Trump's policy prescriptions (“TrumpRx”) to climate regulations, internet addiction, Discord culture, SpaceX's ambitions, and Russia's geopolitical threat.No topic is safe. No sacred cows spared.If you care about capitalism, individual rights, Elon Musk, government overreach, the FDA, Putin, or the future of freedom — this episode delivers clarity you won't hear anywhere else.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's returning guests are Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture capital investor for Time BioVentures. In today's episode, we unpack the recent biotech surge through the lens of Dan's recently published biotech report. We also explore China's growing biotech market, shifting IPO and VC trends, and how valuation tools like CAPE fit into today's regime. Finally, we also discuss technology's effect on productivity and corporate profits in the US, Japan's economic anomaly, home country bias, and more. (0:00) Starts (1:20) Dan's research on the biotech sector (19:10) D.A. on biotech in China (27:01) IPO landscape (31:01) Biotech VC update from D.A. (32:16) Are US stocks overvalued? (51:53) Dan's view of Japanese stocks (57:40) Global equity markets and home country bias (1:03:34) Book recommendations (1:11:55) Wrap-up and future plans ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- ⁠ ----- Sponsor: Visit ⁠⁠Alpha Architect's 351 Education Center⁠⁠ for use cases, tools, FAQs, upcoming launches, and more. Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices